Vir Biotechnology, Inc. (VIR) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on infectious diseases (specifically chronic hepatitis delta) and oncology (dual-masked T-cell engagers). The company operates as a single reportable segment.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6 Months 2026 | 6 Months 2025 |
|---|---|---|---|---|
| Total Revenues | $238,946 | $1,214 | $238,917 | $4,246 |
| Net Income (Loss) | $80,080 | $(110,958) | $(45,615) | $(231,923) |
| Operating Expenses | $165,479 | $119,631 | $297,740 | $262,210 |
| Cash & Investments | $1.01 billion (as of June 30, 2026) | |||
| Accumulated Deficit | $1.24 billion (as of June 30, 2026) |
Liquidity: The company holds approximately $1.01 billion in cash, cash equivalents, and investments, sufficient to fund operations for at least 12 months. There is no debt outstanding.
Material Changes vs. Prior Period
- Revenue Surge: Q2 2026 revenue increased to $238.9 million from $1.2 million in Q2 2025. This is primarily driven by a $239.3 million upfront payment recognized from a new collaboration with Astellas US LLC regarding the VIR-5500 prostate cancer program.
- Profitability Shift: The company reported a net income of $80.1 million for Q2 2026, compared to a net loss of $111.0 million in the prior year quarter. The six-month period remained in a net loss of $45.6 million due to high operating costs.
- Operating Expenses: R&D expenses increased to $135.3 million in Q2 2026 (from $97.5 million in Q2 2025), driven by a $48 million payment to Sanofi related to the Astellas deal and increased manufacturing/clinical costs. SG&A increased to $30.2 million due to one-time legal and advisory fees for the Astellas agreement.
- Capital Raise: In February 2026, the company completed a follow-on public offering, raising approximately $162.2 million net proceeds.
Guidance, Outlook, and Risks
- Collaboration Milestones: The Astellas agreement includes potential future milestones of up to $1.39 billion and tiered royalties. Vir Bio will share development costs (40% Vir, 60% Astellas) and profits/losses equally in the U.S.
- Clinical Pipeline:
- CHD (Hepatitis Delta): The ECLIPSE registrational program is fully enrolled. Topline data for ECLIPSE 1 is expected in Q4 2026.
- Oncology: Phase 1 trials for VIR-5500 (prostate), VIR-5818 (HER2), and VIR-5525 (EGFR) are advancing. Pivotal Phase 3 trials for VIR-5500 are anticipated in 2027.
- Management Changes: The CFO, Jason O'Byrne, is stepping down effective August 3, 2026. Brent Sabatini (Chief Accounting Officer) has been appointed interim Principal Financial Officer. The former CMO, Mark Eisner, also departed in April 2026.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for substantial additional funding in the future, reliance on third-party manufacturers (CDMOs), and potential dilution from future capital raises.
Investor Verification Checklist
- Astellas Deal Economics: Verify the specific terms of the $240 million upfront payment and the $75 million stock purchase, including the allocation of future milestones and profit-sharing obligations.
- Sanofi Payment: Confirm the impact of the $48 million payment to Sanofi (recorded as R&D expense) on future cash flow and milestone obligations.
- Cash Burn Rate: Assess the sustainability of the $1.01 billion cash position given the increased R&D spend and the timeline for the next major capital raise.
- Leadership Transition: Monitor the search for a permanent CFO and CMO to ensure operational continuity.
- Clinical Data Readouts: Track the Q4 2026 top-line data release for the ECLIPSE 1 trial, which is critical for the CHD program's regulatory path.